Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $13.8 million.

  • Pharmaceuticals' Other Non-Current Liabilities fell 9990.3% to $13.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.8 million, marking a year-over-year decrease of 9990.3%. This contributed to the annual value of $15.4 million for FY2024, which is 9990.07% down from last year.
  • Pharmaceuticals' Other Non-Current Liabilities amounted to $13.8 million in Q2 2025, which was down 9990.3% from $15.2 billion recorded in Q1 2025.
  • Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $15.5 billion during Q4 2023, with a 5-year trough of $12.3 million in Q4 2022.
  • Over the past 5 years, Pharmaceuticals' median Other Non-Current Liabilities value was $15.4 million (recorded in 2024), while the average stood at $6.3 billion.
  • In the last 5 years, Pharmaceuticals' Other Non-Current Liabilities soared by 12580062.62% in 2023 and then crashed by 9990.3% in 2025.
  • Over the past 5 years, Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $14.3 million in 2021, then decreased by 14.16% to $12.3 million in 2022, then surged by 125800.63% to $15.5 billion in 2023, then crashed by 99.9% to $15.4 million in 2024, then decreased by 10.38% to $13.8 million in 2025.
  • Its Other Non-Current Liabilities stands at $13.8 million for Q2 2025, versus $15.2 billion for Q1 2025 and $15.4 million for Q4 2024.